Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.
de la Fouchardière C, Gamradt P, Chabaud S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S, Cattey-Javouhey A, Guibert P, Sarabi M, Rochefort P, Funk-Debleds P, Coutzac C, Ray-Coquard I, Peyrat P, Meeus P, Rivoire M, Dupré A, Hennino A. de la Fouchardière C, et al. Among authors: sarabi m. J Pers Med. 2022 Apr 12;12(4):623. doi: 10.3390/jpm12040623. J Pers Med. 2022. PMID: 35455739 Free PMC article.
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer.
Cohen R, Jonchère V, De La Fouchardière C, Ratovomanana T, Letourneur Q, Ayadi M, Armenoult L, Buisson A, Sarabi M, Pellat A, Colle R, Paye F, Meeus P, Svrcek M, Duval A, Andre T. Cohen R, et al. Among authors: sarabi m. J Immunother Cancer. 2021 Feb;9(2):e001903. doi: 10.1136/jitc-2020-001903. J Immunother Cancer. 2021. PMID: 33579738 Free PMC article.
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, Cunha AS, Vienot A, Lecomte T, Hautefeuille V, de La Fouchardière C, Sarabi M, Ksontini F, Forestier J, Coriat R, Fabiano E, Leroy F, Williet N, Bachet JB, Tougeron D, Taieb J. Auclin E, et al. Among authors: sarabi m. Br J Cancer. 2021 Jun;124(12):1941-1948. doi: 10.1038/s41416-021-01341-w. Epub 2021 Mar 26. Br J Cancer. 2021. PMID: 33772154 Free PMC article.
Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C. Rochefort P, et al. Among authors: sarabi m. Immunotherapy. 2021 Oct;13(14):1205-1213. doi: 10.2217/imt-2021-0024. Epub 2021 Sep 8. Immunotherapy. 2021. PMID: 34494466 Review.
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Varnier R, et al. Among authors: sarabi m. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. Front Oncol. 2021. PMID: 34631593 Free PMC article.
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A. Palle J, et al. Among authors: sarabi m. Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254172 Free PMC article.
95 results